Royalty Rates in Biotech Deals, Part I
Royalty rates in biotech deals are determined by a variety of factors; most important is the level of risk the product represents at the stage it is licensed.
You may also be interested in...
With the Janssen and Novavax deals, the UK has now secured access to six different candidates across four different vaccine types.
Council of Europe Directorate EDQM finds popular paracetamol products sold in the Netherlands and manufactured in China do not contain unsafe levels of a possible human carcinogen as reported in the Dutch media.
Perrigo launches new XLS-Medical Ultra 5 slimming aid just in time for the UK government's new weight-loss drive in response to the COVID-19 pandemic.